XTL Biopharmaceuticals Ltd. (XTLB)

NCM – Real vaqt narxi. Valyuta: USD

2.36

-0.20 (-7.99%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

2.36

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

XTL Biopharmaceuticals Ltd. (XTLB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Announces Receipt of Staff Delist Determination from Nasdaq

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Videolar

No Data

Press-relizlar

XTL Announces Receipt of Staff Delist Determination from Nasdaq

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

Search stocks

XTL Biopharmaceuticals Ltd. (XTLB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Announces Receipt of Staff Delist Determination from Nasdaq

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Videolar

No Data

Press-relizlar

XTL Announces Receipt of Staff Delist Determination from Nasdaq

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing